Table 5.
Name of Substances/Compound | Dose | Model | Observations | Reference |
---|---|---|---|---|
Kaempferol | 5 and 25 μM for 24 h | High glucose-stimulated HRECs | ↓ VEGF and PGF mRNA levels | [100] |
↓ cell proliferation, migration, migration distance and sprouting of HRECs | ||||
↓ PI3K expression and ERK1/2, Src, and Akt1 activation | ||||
10, 15, 20, 25, 30 and 35 µM | N/A | ↓ α-glucosidase and α-amylase activities | [101] | |
Quercetin | 25 and 50 mg/kg orally administered for 24 weeks | STZ-induced T1DM rats | ↑ GSH levels | [103] |
↑ SOD and CAT activities | ||||
↑ ganglion cells number and retinal thickness | ||||
↓ TNF-α and IL-1β levels | ||||
↓ NF-kB and caspase-3 levels | ||||
↓ GFAP and aquaporin-4 levels | ||||
150 mg/kg by intragastric injection for 20 weeks | STZ-induced T1DM rats | ↓ MMP-9 and VEGF serum levels | [102] | |
↓ MMP-9 and VEGF RNA and protein levels | ||||
10, 20, 30, 40 and 50 μM for 24 h | High glucose-exposed ARPE-19 cells | ↑ CyclinD1, CDK4 and Bcl-2 levels | [104] | |
↑ MiR-29b expression | ||||
↑ PTEN/AKT pathway | ||||
↓ NF-κB pathway via a miR-29b-dependent way | ||||
↓ viability loss, apoptosis, MCP-1 and IL-6 production and ROS generation | ||||
↓ p53, Bax and cleaved-caspase-3 expression | ||||
Rutin | 100 mg/kg orally administered for 5 weeks | STZ-induced T1DM rats | ↑ blood insulin levels | [106] |
↑ Bcl-2 levels | ||||
↑ BDNF, NGF and GSH | ||||
↓ blood glucose levels | ||||
↓ TBARs | ||||
↓ caspase-3 levels | ||||
50 mg/kg orally administered for 24 weeks | STZ-induced T1DM rats | ↑ total antioxidant capacity of the retinas | [107] | |
↓ VEGF, TNF-α and aldose reductase protein levels | ||||
↓ vascular leakage of fluorescein | ||||
Galangin | 20 and 50 μM for 6 h | D-glucose-stimulated microglial BV2 cells | ↓ BRB damage | [108] |
↓ ROS formation | ||||
↓ microglia cells activation | ||||
↓ ERK1/2 phosphorylation | ||||
↓ NF-κB and Egr1 protein levels | ||||
↓ TNF-α levels | ||||
20 and 50 μM for 6 h | TNF-α-exposed HRECs and ARPE-19 cells | ↑ claudin-1 and occludin levels | ||
↑ Nrf2 activation | ||||
↓ BRB damage | ||||
↓ ROS formation | ||||
1 and 10 mg/kg injection for 1 month | STZ-induced T1DM mice | ↓ BRB damage | ||
↓ ROS formation | ||||
↓ microglia cells activation | ||||
↓ ERK1/2 phosphorylation, NF-κB Egr1 protein | ||||
↓ TNF-α levels | ||||
Myricetin | N/A | AGE-BSA-exposed bovine retinal pericytes | ↓ pericytes migration | [109] |
↓ ERK1/2-FAK-1-paxillin phosphorylation | ||||
5 or 10 mM intravitreally injection | AGE-BSA-intravitreally injected rats | ↓ pericytes migration | ||
↓ ERK1/2-FAK-1-paxillin phosphorylation | ||||
2.5, 5, 10, 20 and 40 μg/mL for 4 h | Glucose oxidase-exposed ARPE-19 cells | ↑ Nrf2 and SOD2 levels | [110] | |
↓ production of H2O2 and intracellular ROS | ||||
↓ nitric oxide producer transcription | ||||
0.02, 0.2, 2, 20 and 40 μg/mL for 48 h | High glucose-exposed ARPE-19 cells | ↑ antioxidant proteins and other protective factors | [111] | |
↑ Nrf2 pathway | ||||
↓ intracellular ROS levels and | ||||
AGE formation | ||||
↓ NFkB1 expression | ||||
and RAGE | ||||
Icariin | 5 mg/kg orally administered for 12 weeks | STZ-induced T1DM rats | ↑ RECA, Thy-1, Brn3a, and Collagen IV and CA-II levels | [112] |
↑ VEGF levels | ||||
0, 10, 100 and 1000 nmol/mL for 3 days | RGC cells from control and diabetic rats | ↑ neurite growth |
AGE: advanced glycation end products, AKT: protein kinase B, ARPE-19: human retinal pigment epithelial cell line, Bax: Bcl-2 associated X protein, Bcl-2: B cell lymphoma-2 protein, BDNF: brain-derived neurotrophic factor, BRB: blood–retinal barrier, Brn3a: brain-specific homeobox/POU domain protein 3A, BSA: bovine serum albumin, CA-II: carbonic anhydrase II, CAT: catalase, CDK4: cyclin-dependent kinase 4, Egr1: early growth response protein 1, ERK1/2: extracellular signal-regulated protein kinases 1 and 2, FAK-1: focal adhesion kinase 1, GFAP: glial fibrillary acidic protein, GSH: glutathione, H2O2: hydrogen peroxide, HRECs: human retinal endothelial cells, IL-1β: interleukin-1β, IL-6: interleukin-6, MCP-1: monocyte chemoattractant protein, miR-29b, microRNA-29b, MMP-9: metalloproteinase-9, N/A: not applicable, NF-κB: nuclear factor kappa-B, NFkB1, nuclear factor of kappa light polypeptide gene enhancer in B-cells 1, NGF: nerve growth factor, Nrf2: nuclear factor erythroid 2-related factor-2, PGF: placenta growth factor, PI3K: phosphoinositide 3-kinase, PTEN, phosphatase and tensin homolog deleted on chromosome 10, RAGE: AGE receptor, RECA: rat endothelial cell antigen, RGC: retinal ganglion cell, ROS: reactive oxygen species, SOD: superoxide dismutase, STZ: streptozotocin, T1DM: type 1 diabetes mellitus, TBARs: thiobarbituric acid reactive substances, TNF-α: tumor necrosis factor alfa, VEGF: vascular endothelial growth factor, ↑: increase, ↓ decrease.